Prilenia

📍 Boston, United States🗓 Founded 2018👥 51 employees💰 Last funded Mar 2022
Biotechnology Research🌐 prilenia.com
Website LinkedIn
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
United Kingdom
1
Frequently asked questions
Who invested in Prilenia?
Prilenia has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Prilenia last raise funding?
The most recent investment in Prilenia recorded on gritt.io was in March 2022.
When was Prilenia founded?
Prilenia was founded in 2018.
What industry is Prilenia in?
Prilenia operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Prilenia based?
Prilenia is headquartered in Boston, United States.